Fig. 1From: PET/CT imaging for tumour response assessment to immunotherapy: current status and future directionsA Hodgkin lymphoma patient with metabolically active tumour manifestations prior to the initiation of immunotherapy with nivolumab. A complete metabolic response already 8 weeks after immunotherapy initiation despite remaining morphological masses on CT was observedBack to article page